biotech / news / / STAT
Clear blue skies and chilly breezes greet us today.
Eli Lilly's gene-editing therapy reduced LDL cholesterol by 62% in a Phase 1 trial.
KEY POINTS
- There were no treatment-related serious adverse events reported in this early study.
- Lilly acquired this gene-editing therapy through its $1 billion buyout of Verve Therapeutics.
- Lilly's next step is a Phase 2 trial, with large Phase 3 trials likely required for approval.
COMPANIES
Summarized by Newsio from STAT. How we summarize →